| Viral proteases: Structure, mechanism and inhibition J Zephyr, NK Yilmaz, CA Schiffer The Enzymes 50, 301-333, 2021 | 46 | 2021 |
| Drug design strategies to avoid resistance in direct-acting antivirals and beyond AN Matthew, F Leidner, GJ Lockbaum, M Henes, J Zephyr, S Hou, ... Chemical reviews 121 (6), 3238-3270, 2021 | 43 | 2021 |
| Hepatitis C virus NS3/4A protease inhibitors incorporating flexible P2 quinoxalines target drug resistant viral variants AN Matthew, J Zephyr, CJ Hill, M Jahangir, A Newton, CJ Petropoulos, ... Journal of medicinal chemistry 60 (13), 5699-5716, 2017 | 41 | 2017 |
| Avoiding drug resistance by substrate envelope-guided design: Toward potent and robust HCV NS3/4A protease inhibitors AN Matthew, J Zephyr, D Nageswara Rao, M Henes, W Kamran, ... MBio 11 (2), 10.1128/mbio. 00172-20, 2020 | 16 | 2020 |
| Discovery of quinoxaline-based p1–p3 macrocyclic ns3/4a protease inhibitors with potent activity against drug-resistant hepatitis C virus variants D Nageswara Rao, J Zephyr, M Henes, ET Chan, AN Matthew, ... Journal of medicinal chemistry 64 (16), 11972-11989, 2021 | 11 | 2021 |
| Viral proteases: structure, mechanism and inhibition. Enzymes 50: 301-333 J Zephyr, N Kurt Yilmaz, CA Schiffer | 8 | 2021 |
| Deciphering the molecular mechanism of HCV protease inhibitor Fluorination as a general approach to avoid drug resistance J Zephyr, DN Rao, SV Vo, M Henes, K Kosovrasti, AN Matthew, ... Journal of molecular biology 434 (9), 167503, 2022 | 6 | 2022 |
| Avoiding drug resistance by substrate envelope-guided design: toward potent and robust HCV NS3/4A protease inhibitors. mBio 11 (2): e00172-20 AN Matthew, J Zephyr, D Nageswara Rao, M Henes, W Kamran, ... | 5 | 2020 |
| Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease J Zephyr, DN Rao, C Johnson, AM Shaqra, EA Nalivaika, A Jordan, ... Bioorganic chemistry 131, 106269, 2023 | 3 | 2023 |
| FruitFire: a luciferase based on a fruit fly metabolic enzyme ST Adams Jr, J Zephyr, MF Bohn, CA Schiffer, SC Miller bioRxiv, 2023 | | 2023 |
| Hepatitis c virus ns3/4a protease inhibitors CA Schiffer, A Ali, J Zephyr, AN Matthew, NR Desaboini US Patent App. 17/607,886, 2022 | | 2022 |
| Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants NR Desaboini, J Zephyr, M Henes, ET Chan, AN Matthew, A Hedger, ... | | 2021 |
| Robust Drug Design Strategies and Discovery Targeting Viral Proteases J Zephyr | | 2021 |
| Avoiding Drug Resistance by Substrate Envelope Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors J Zephyr, AN Matthew, DN Rao, M Henes, W Kamran, AK Hedger, ... The FASEB Journal 34 (S1), 1-1, 2020 | | 2020 |
| Let us know how access to this document benefits you. LL Heckert | | 1976 |
